Circulating tumor DNA in HER2 amplified breast cancer: a translational research substudy of the NeoALTTO phase 3 trial
de Azambuja, E
Di Cosimo, S
Wardley, Andrew M
AffiliationBreast Cancer Translational Research Laboratory, Queen's University Belfast
MetadataShow full item record
AbstractPURPOSE: In the neoadjuvant treatment (NAT) setting, dual human epidermal growth factor receptor 2 (HER2) targeted therapy is associated with increased pathological complete response (pCR) rates compared to each therapy alone. Biomarkers allowing to predict treatment response during NAT are needed. We aim to evaluate whether circulating tumor DNA (ctDNA) is associated with response to anti-HER2 targeted therapy. EXPERIMENTAL DESIGN: Plasma DNA collected before NAT, at week2 and before surgery from patients enrolled in the NeoALTTOtrialwas assessed using digital PCR for PIK3CA and TP53 mutation detection. RESULTS: A total of 69 of 455 (15.2%) patients had a PIK3CA and/or TP53 mutation detected in the baseline tumor sample and evaluable ctDNA results from baseline samples. CtDNA was detected in 41%, 20% and 5% patients before NAT, at week 2 and before surgery respectively. CtDNA detection before NAT was significantly associated with older age and ER-negative status. CtDNA detection before NAT was associated with decreased odds of achieving pCR (OR 0.15, 95%CI 0.034-0.7, p=0.0089) but not with event-free survival (EFS). Analyses for EFS were underpowered. Interestingly, the patients with HER2 enriched subtype tumors and undetectable ctDNA at baseline had the highest pCR rates. By contrast, patients with persistent ctDNA detection at baseline and week 2 had the lowest rate of pCR. CONCLUSIONS: CtDNA detection before neoadjuvant anti-HER2 therapies is associated with decreased pCR rates. Interestingly, patients with HER2 enriched tumors and undetectable ctDNA at baseline had the highest pCR rates, therefore appearing as the best candidates for treatment de-escalation strategies.
CitationRothe F, Silva MJ, Venet D, Campbell C, Bradbury I, Rouas G, et al. Circulating tumor DNA in HER2 amplified breast cancer: a translational research substudy of the NeoALTTO phase 3 trial. Clin Cancer Res. 2019.
JournalClinical Cancer Research
- RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
- Authors: Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Peña L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C
- Issue date: 2017 Feb 1
- Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial.
- Authors: Azim HA Jr, Rothé F, Aura CM, Bavington M, Maetens M, Rouas G, Gebhart G, Gamez C, Eidtmann H, Baselga J, Piccart-Gebhart M, Ellis C, Vuylsteke P, Cure H, Domont J, Ferro A, Toral-Peña JC, de Azambuja E, Sotiriou C, Di Cosimo S, Ignatiadis M
- Issue date: 2013 Dec
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
- Authors: Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S
- Issue date: 2015 Jul
- ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
- Authors: Ma F, Zhu W, Guan Y, Yang L, Xia X, Chen S, Li Q, Guan X, Yi Z, Qian H, Yi X, Xu B
- Issue date: 2016 Oct 4
- Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
- Authors: Riva F, Bidard FC, Houy A, Saliou A, Madic J, Rampanou A, Hego C, Milder M, Cottu P, Sablin MP, Vincent-Salomon A, Lantz O, Stern MH, Proudhon C, Pierga JY
- Issue date: 2017 Mar